AQP2 and Ascites: In line with these findings, recent data indicate that AQP2 excretion can be considered a novel non‐invasive marker to predict the response to tolvaptan in patients with congestive and decompensated heart failure 42, 43 and has recently been found to correlate with the pharmacological effect of tolvaptan in cirrhotic patients with ascites 44.